Luca is renowned as a top name in M&A and corporate finance. One source says, ‘Luca combines his legal knowledge with a practical and client-oriented approach,” adding, “He can work under pressure and is very proactive’.” WHO’S WHO LEGAL 2018 – M&A and Governance (Italy)
Luca has been ranked as leading practitioner in the Life Sciences sector and M&A and Corporate Governance in the 2018 Who’s Who Legal guide.
He focuses his practice in domestic and cross border M&A, private equity, and venture capital transactions acting for investors and companies at all stages of development across the spectrum of life sciences and technology industries, including biotechnology, medical devices, pharmaceutical, and digital/information technology.
He has also gained a strong and extensive experience on commercial contracts for clients operating in the Life Sciences industries, including the drafting and negotiation of pharmaceutical products’ manufacturing, supply, distribution and co-marketing contracts, as well as clinical trials and proctoring agreements, and other commercial and IT agreements.
Luca contributes regularly to newsletters and journals on M&A and Life Sciences topics; he authored the articles “Pros And Cons of Earn-Out Construct in Life Sciences Merger and Acquisition Transactions” and “How to survive to financial crisis, political changes and other adverse events: an overview of MAC clauses in recent transactions with an in-depth analysis of the Abbott Laboratories/Alere Inc. case” (both articles published by Bocconi Legal Papers), and he co-authored the Italian chapter of The Life Sciences Law Review and contributed to the ABA European Private Target M&A Deal Points Study 2017. He regularly publishes articles on Life Sciences matters on the online magazine AboutPharma.
Prior to joining the firm he completed an internship with a law firm in Washington DC and he has been on secondment at the M&A and Private Equity department of Morrison & Foerster LLP in New York City, assisting some of the main US and Canadian private equity funds.
Foreign languages: English (speaking proficiency).